JP2023531090A5 - - Google Patents

Info

Publication number
JP2023531090A5
JP2023531090A5 JP2022580273A JP2022580273A JP2023531090A5 JP 2023531090 A5 JP2023531090 A5 JP 2023531090A5 JP 2022580273 A JP2022580273 A JP 2022580273A JP 2022580273 A JP2022580273 A JP 2022580273A JP 2023531090 A5 JP2023531090 A5 JP 2023531090A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
region containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022580273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531090A (ja
JP7799638B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/103687 external-priority patent/WO2022002153A1/zh
Publication of JP2023531090A publication Critical patent/JP2023531090A/ja
Publication of JP2023531090A5 publication Critical patent/JP2023531090A5/ja
Application granted granted Critical
Publication of JP7799638B2 publication Critical patent/JP7799638B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022580273A 2020-06-30 2021-06-30 腫瘍を治療するための薬物 Active JP7799638B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010619083.8 2020-06-30
CN202010619111.6 2020-06-30
CN202010619083 2020-06-30
CN202010619111 2020-06-30
CN202010620778.8 2020-06-30
CN202010620778 2020-06-30
PCT/CN2021/103687 WO2022002153A1 (zh) 2020-06-30 2021-06-30 用于治疗肿瘤的药物

Publications (3)

Publication Number Publication Date
JP2023531090A JP2023531090A (ja) 2023-07-20
JP2023531090A5 true JP2023531090A5 (cg-RX-API-DMAC7.html) 2024-07-09
JP7799638B2 JP7799638B2 (ja) 2026-01-21

Family

ID=79317451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580273A Active JP7799638B2 (ja) 2020-06-30 2021-06-30 腫瘍を治療するための薬物

Country Status (7)

Country Link
US (1) US20230310596A1 (cg-RX-API-DMAC7.html)
EP (1) EP4174087A4 (cg-RX-API-DMAC7.html)
JP (1) JP7799638B2 (cg-RX-API-DMAC7.html)
CN (1) CN115698076A (cg-RX-API-DMAC7.html)
AU (1) AU2021301947A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188017A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022002153A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116209443A (zh) * 2021-08-05 2023-06-02 正大天晴药业集团股份有限公司 治疗小细胞肺癌的药物组合
WO2023232100A1 (zh) * 2022-06-02 2023-12-07 正大天晴药业集团股份有限公司 用于治疗子宫恶性肿瘤的药物组合

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201901057UA (en) * 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
US9751859B2 (en) * 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
KR102642385B1 (ko) * 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3576765B1 (en) * 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
US20210147547A1 (en) * 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN110734493B (zh) * 2018-07-20 2021-12-17 厦门大学 抗pd-1抗体及其用途
CN118267468A (zh) * 2019-01-25 2024-07-02 正大天晴药业集团股份有限公司 治疗肿瘤的联用药物组合物
CN112168961A (zh) * 2019-07-03 2021-01-05 正大天晴药业集团南京顺欣制药有限公司 治疗结直肠癌的联用药物组合物

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2019517549A5 (cg-RX-API-DMAC7.html)
RU2019133787A (ru) Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
JP2021511372A5 (cg-RX-API-DMAC7.html)
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
JP2015500822A5 (cg-RX-API-DMAC7.html)
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
FI3463345T3 (fi) Farmaseuttisia yhdistelmiä
WO2023061472A1 (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
JP2023510199A5 (cg-RX-API-DMAC7.html)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
CN119424632A (zh) 治疗结直肠癌的联用药物组合物
JP2022530599A5 (cg-RX-API-DMAC7.html)
JP2024527974A5 (cg-RX-API-DMAC7.html)
CN116209443A (zh) 治疗小细胞肺癌的药物组合
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
CN115698076A (zh) 用于治疗肿瘤的药物
JP2023500480A5 (cg-RX-API-DMAC7.html)
JP2022549218A5 (cg-RX-API-DMAC7.html)
CN120752053A (zh) 含抗tim-3抗体的药物组合
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
WO2024051670A1 (zh) 结合tim-3的抗体与结合pd-1的抗体的药物组合
TWI671072B (zh) 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合
CN112543637B (zh) 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途